Immunotherapy in autoimmune encephalitis
BP Trewin, I Freeman, S Ramanathan… - Current Opinion in …, 2022 - journals.lww.com
Early first-line immunotherapies, including corticosteroids and plasma exchange, improve
outcomes, with emerging evidence showing second-line immunotherapies (especially …
outcomes, with emerging evidence showing second-line immunotherapies (especially …
Management of autoimmune encephalitis
CG Bien - Current opinion in neurology, 2021 - journals.lww.com
Management of autoimmune encephalitis : Current Opinion in Neurology Management of
autoimmune encephalitis : Current Opinion in Neurology Log in or Register Subscribe to …
autoimmune encephalitis : Current Opinion in Neurology Log in or Register Subscribe to …
Prospective quantification of CSF biomarkers in antibody-mediated encephalitis
GS Day, MY Yarbrough, P Körtvelyessy, H Prüss… - Neurology, 2021 - AAN Enterprises
Objective To determine whether neuronal and neuroaxonal injury, neuroinflammation, and
synaptic dysfunction associate with clinical course and outcomes in antibody-mediated …
synaptic dysfunction associate with clinical course and outcomes in antibody-mediated …
A systematic review and quantitative synthesis of the long-term psychiatric sequelae of pediatric autoimmune encephalitis
Background Long-term neuropsychiatric sequelae of autoimmune encephalitis (AE) remain
understudied, particularly in pediatric-onset AE. We aimed to synthesize the published data …
understudied, particularly in pediatric-onset AE. We aimed to synthesize the published data …
Allosteric modulation of NMDARs reverses patients' autoantibody effects in mice
M Radosevic, J Planagumà, F Mannara… - Neurology …, 2021 - AAN Enterprises
Background and Objectives To demonstrate that an analog (SGE-301) of a brain-derived
cholesterol metabolite, 24 (S)-hydroxycholesterol, which is a selective positive allosteric …
cholesterol metabolite, 24 (S)-hydroxycholesterol, which is a selective positive allosteric …
Clinical outcome assessments in encephalitis: a systematic review
J Brenner, SHC Olijslagers, YS Crijnen… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Most patients with encephalitis experience persisting
neurocognitive and neuropsychiatric sequelae in the years following this acute illness …
neurocognitive and neuropsychiatric sequelae in the years following this acute illness …
Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults
Background and objectives To evaluate residual symptoms after all-cause autoimmune
encephalitis in a real-life outpatient setting and compare long-term outcome measures. A …
encephalitis in a real-life outpatient setting and compare long-term outcome measures. A …
Younger age at onset is associated with worse long-term behavioral outcomes in anti-NMDA receptor encephalitis
A Yeshokumar, E Gordon-Lipkin… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Anti-NMDA receptor encephalitis (anti-NMDARE) is one of the
most common causes of encephalitis. It typically presents in adolescence and young …
most common causes of encephalitis. It typically presents in adolescence and young …
Assessment of long-term psychosocial outcomes in N-methyl-D-aspartate receptor encephalitis–the SAPIENCE study protocol
OJ Boeken, J Heine, M Duda-Sikula, V Patricio… - BMC neurology, 2024 - Springer
Background N-methyl-D-aspartate-receptor (NMDAR) encephalitis is a rare neurological
autoimmune disease with severe neuropsychiatric symptoms during the acute phase …
autoimmune disease with severe neuropsychiatric symptoms during the acute phase …
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG …
Background Autoimmune encephalitis (AIE) encompasses a spectrum of rare autoimmune-
mediated neurological disorders, which are characterized by brain inflammation and …
mediated neurological disorders, which are characterized by brain inflammation and …